Abpro Corporation (ABP) Research

Abpro Holdings, Inc. is a biotechnology firm dedicated to creating antibody-based treatments for patients suffering from conditions in immuno-oncology, ophthalmology, and autoimmunity. A key element of their strategy is the proprietary DiversImmune platform, which aims to resolve a significant hurdle in the antibody therapeutics sector. Their primary investigational drug candidates include ABP-100, designed to target breast, gastric, and colorectal cancers, and ABP-201, intended for the treatment of vascular diseases affecting the eye. The company has established strategic alliances with Abpro Bio Co. Ltd and NJCTTQ. Originally known as Abpro Corporation, the company officially changed its name to Abpro Holdings, Inc. in November 2024. Incorporated in 2004, Abpro Holdings, Inc. operates from its headquarters in Woburn, Massachusetts.

Market snapshot

Symbol
ABP
Price
$0.52
Day change
0.00%
Market cap
$525.3K
P/E ratio
-92.10x
52-week range
0.11-18.03
Sector
Healthcare
Industry
Biotechnology

Peer companies

  • AEON Biopharma, Inc. (AEON)
  • Aptorum Group Limited (APM)
  • Bolt Biotherapeutics, Inc. (BOLT)
  • Cingulate Inc. (CING)
  • Cellectar Biosciences, Inc. (CLRB)
  • Evogene Ltd. (EVGN)
  • Lyra Therapeutics, Inc. (LYRA)
  • Mustang Bio, Inc. (MBIO)

Open Abpro Corporation (ABP) in Thesis for live fundamentals, charts, options context, and portfolio-aware Copilot follow-ups.